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Copyright © 2009 JCBN Summary In this study, we investigated the mechanistic role of the caspase cascade in extrinsic
and intrinsic apoptosis induced by apigenin, which has been targeted as a candidate in the
development of noncytotoxic anticancer medicines. Treatment with apigenin (1–100 µM)
significantly inhibited the proliferation of MDA-MB-453 human breast cancer cells in a dose-
and time-dependent manner with IC50 values of 59.44 and 35.15 µM at 24 and 72 h, respec-
tively. This inhibition resulted in the induction of apoptosis and the release of cytochrome c in
cells exposed to apigenin at its 72 h IC50. Subsequently, caspase-9, which acts in mitochondria-
mediated apoptosis, was cleaved by apigenin. In addition, apigenin activated caspase-3, which
functions downstream of caspase-9. The apigenin-induced activation of caspase-3 was accom-
panied by the cleavage of capases-6, -7, and -8. These results are supported by evidence
showing that the activity patterns of caspases-3, -8, and -9 were similar. The present study
supports the hypothesis that apigenin-induced apoptosis involves the activation of both the
intrinsic and extrinsic apoptotic pathways.
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Introduction
Recently, flavonoids have been suggested as being
potential chemotherapeutic agents owing to their biological
activities, which include effects on cell cycle arrest and
the induction of apoptosis [1–4]. Apigenin (4',5,7-
trihydroxyflavone), a member of the flavone subclass of
flavonoids, is present in fruits and vegetables [5] and is
believed to have a number of biological functions including
anti-inflammatory, anticancer, and free-radical scavenging
properties [6–9]. Studies of human malignant cancer cell
lines have shown that apigenin inhibits cancer cell growth
via the promotion of cell cycle arrest and apoptosis [10, 11].
Moreover, apigenin is reportedly nonmutagenic and of low
toxicity compared to related flavonoids [12]. Thus, apigenin
may be a good candidate compound for anticancer drugs.
Apoptosis, or programmed cell death, is a multi-step
process that is important in controlling cell number and
proliferation as part of normal development; however,
cancer cells tend to inactivate the cell cycle checkpoints and
the subsequent progression of apoptosis. Consequently, the
induction of apoptosis has been emphasized in anticancer
strategies [13, 14]. Regarding the initiation and execution of
cell death, two apoptosis pathways have been identified: the
extrinsic (Fas death receptor-mediated) and intrinsic (mito-
chondrial) pathways. Both pathways involve the activation
of caspases, a family of cysteine proteases that are activated
in a sequential cascade of cleavage by other caspase family
members [15, 16].
Evidence that several flavonoids activate the proteolytic
activities of caspases supports their value as potential anti-
cancer agents for controlling tumor growth [17–21]. One
major pathway of caspase-activated apoptosis is triggered by
the release of cytochrome c from the mitochondria to the
cytoplasm. Previously our study, apigenin treatment resultsApigenin Induced Caspase-dependent Apoptosis
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in apoptotic cell death via up-regulation of cytochrome c
expression in human breast SK-BR-3 cells [22]. It has been
reported that apigenin is a candidate therapeutic for neuro-
blastoma that likely acts by regulating a p53-Bax-caspase-3
apoptotic pathway [23].
However, the mechanisms underlying the effects of
apigenin in the induction of apoptosis in human breast
cancer cells are still unknown. Therefore, the present study
was conducted to investigate whether the initiator caspase in
the extrinsic or intrinsic pathway is activated during the
induction of apoptosis by apigenin in MDA-MB-453 human
breast cancer cells.
Materials and Methods
The cells culture and apigenin treatment
Human breast cancer MDA-MB-453 cells were pur-
chased from the KCLB (Korean Cell Line Bank, Seoul,
Korea). Cells was routinely maintained in RPMI 1640
(Invitrogen [Molecular Probes], Gibco, Carlsbad, CA),
supplemented with 10% FBS and antibiotics (50 U/ml of
penicillin and 50 µg/ml streptomycin, Gibco) at 37°C in a
humidified atmosphere containing 5% CO2. For cell pro-
liferation assay, cells were treated with apigenin ranging
from 1 to 100 µM and incubated for 24 and 72 h. Then after,
to investigate the apoptosis induction by apigenin, cells were
exposed to either vehicle or apigenin (at the IC50 concentra-
tion) and incubated for 72 h. Apigenin was purchased from
Sigma and dissolved in DMSO (final concentration 0.1% in
medium, Sigma-Aldrich Corp., St. Louis, MO).
Cell proliferation assay
The inhibitory effect of the apigenin on cell proliferation
was determined by the MTT assay. The cells were treated
with apigenin ranging from 1 to 100 µM and incubated for
24 and 48 h and added to methyl thiazolyl tetrazolium
(MTT). Four hours later, DMSO was added to each well to
dissolve the resulting formazan crystals and then absorbance
was recorded at 490 nm in a microplate reader (SpectraMax
Plus; Molecular Devices Corp., Orleans, CA). The value of
IC50 (i.e., the concentration of the extract required to inhibit
cancer cell proliferation by 50% of the control level, which
is each cells treated with only compound solvent) was
estimated from the plot.
DAPI staining assay
Apoptotic morphological changes were determined by
DAPI (4',6-diamidino-2-phenyl-indole) staining. After
harvesting the cells exposed with apigenin for 72 h, the
cells were seeded in poly-l-lysine coated slides and fixed
with 4% methanol-free formaldehyde solution for 30 min.
Then mounting medium with DAPI (Molecular Probes,
Eugene, OR) was dispersed over the entire section of slides.
Mounted slides were stored at 4°C without light. Each slide
was observed under Axio vision 4.0 fluorescence micro-
scopes (Carl Zeiss Inc., Thornwood, NY). Additionally,
features of MDA-MB-453 cells exposed to apigenin were
also observed using a Nikon inverse phase contrast micro-
scope (Nikon TMS, Nikon, Tokyo, Japan) equipped with an
objective (Plan 10/0.30DL/Ph1, Nikon) of ×100 magnifica-
tion.
Immunoblotting assay
Protein expression was determined by western blotting.
Briefly, cells were lysed in RIPA buffer (1% NP-40,
150 mM NaCl, 0.05% DOC, 1% SDS, 50 mM Tris, pH 7.5)
containing protease inhibitor for 1 h at 4°C. The supernatant
was separated by centrifugation, and protein concentration
was determined by Bradford protein assay kit II (Bio-rad
Laboratories, Hercules, CA). For detection of cytochrome c
release, cytosolic fraction was sedimented from post-nuclear
supernatant by centrifugation at 100,000 g for 30 min at
4°C. Proteins (25 µg/well) denatured with sample buffer
were separated by 10% SDS-polyacrylamide gel. Proteins
were transferred onto nitrocellulose membranes (0.45 µm).
The membranes were blocked with a 1% BSA solution
for 3 h and washed twice with PBS containing 0.2% Tween-
20, and incubated with the respective primary antibodies
(Cell Signaling Technology, Inc., Danvers, CA) overnight at
4°C. The next day, the immunoreaction was continued with
the secondary goat anti-rabbit horseradish-peroxidase–
conjugated antibody after washing for 2 h at room tempera-
ture. The specific protein bands were detected by Opti-4CN
Substrate kit (Bio-rad).
Colorimetric caspases activity assay
To analyze the role of caspases, caspases activity was
measured using colorimetric assay. Briefly, the single-cell
suspension was collected by centrifugation at 1,000 rpm and
the cells were lysed with lysis buffer (1% Triton X-100,
0.32 M sucrose, 5 mM EDTA, 10 mM Tris-HCl, pH 8.0,
2 mM dithiothreitol, 1 mM PMSF, 1 µg/ml Aprotinin, 1 mg/
ml Leupeptin). Thereafter, the lysates were transferred to
wells in a 96-well flat-bottom microplate and were incu-
bated with 4 mM substrate (final concentration of 200 uM)
specific for caspase-3, -8, and -9 at 37°C for 1 h. Specific
substrate was DVED-pNA for caspase-3, IETD-pNA for
caspase-8 or LEHD-pNA for caspase-9, respectively. The
intensity of the developed color was read at 405 nm in a
microplate reader (SpectraMax Plus; Molecular Devices).
Statistical analyses
All data were expressed as percent compared with
vehicle-treated control cells, which were arbitrarily assigned
100%. Data were analyzed by one-way analysis of variance
followed by Dunnett’s multiple comparison test (Sigma Stat,E.J. Choi et al.
J. Clin. Biochem. Nutr.
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Jandel, San Rafael, CA). For all comparisons, differences
were considered statistically significant at p<0.05.
Results
Apigenin inhibited the cell proliferation
The effects of apigenin on cell proliferation were mea-
sured with the MTT assay, using human breast cancer MDA-
MB-453 cells exposed to between 1 and 100 µM apigenin
for 24 and 72 h (Fig. 1). Statistical differences in cell
proliferation were first exhibited as inhibited cell prolifera-
tion at 10 and 5 µM after 24 and 48 h of apigenin treatment,
respectively (p<0.05). Apigenin exhibited antiproliferative
effects against human breast cancer MDA-MB-453 cells
with the IC50 values of 59.44 and 35.15 µM at 24 and 72 h,
respectively. Cell proliferation dramatically decreased up to
35.10% when treated with 100 µM apigenin for 72 h
compared to the control.
Apigenin induced the apoptosis
To verify that anticancer activity of apigenin in human
breast cancer MDA-MB-453 cells, we observed the
apoptotic feature and performed the DAPI staining as
apoptosis index after exposing cells to apigenin at IC50
concentration (Fig. 2A, B). DAPI stains DNA specifically
by permeating the cell membrane to bind with DNA. DAPI
staining assays revealed that apoptotic morphological
features such as cell shrinkage and dot-shaped nuclear
fragments were observed in exposing cells to apigenin.
Furthermore, these results are supported by Annexin-based
flow cytometry (Fig. 2C). Apigenin increased significantly
the total number of apoptotic cells in the MDA-MB-453
cells treated at its IC50 concentration for 72 h (11.2 and
42.2% in early and late apoptotic cell population, respec-
tively, p<0.05).
Apigenin mediated the caspases cascade
Under the same conditions described above, apigenin-
induced caspase-dependent pathway of apoptotic signal
transduction was evaluated in human breast MDA-MB-453
cells. Caspases are synthesized as relatively inactive
zymogens, which become activated upon cleavage, a
common mechanism for most protease zymogens. Thus, we
observed both the zymogen and the cleaved forms of
caspases.
As shown in Fig. 3A, the release of cytochrome c in the
cytosolic fraction increased remarkably by apigenin treat-
ment. Moreover, Apigenin activated the caspase-3 signifi-
cantly, as evidenced by a decrease in capase-3 accompanied
by an increase of cleaved caspase-3. In parallel with this
result, the activation of caspase-3 in cells exposed to
apigenin induced increased cleavage of caspase-6 and -7.
Beside, the caspase-8 and -9 were decreased significantly
together with an increase of cleaved caspase-9 (Fig. 3B).
To confirm the caspase activations, caspase-3, -8, and -9
were determined using a colorimetric assay. Although three
caspase activities increased significantly by apigenin
treatment, compared to the control, the caspase-3 activity
displayed a greater increase than did capase-8 and -9. The
caspase-3 activity increased by more than 2-fold compared
to the control, while caspase-8 and -9 increased by 1.6- and
1.8-fold, respectively (p<0.05, Fig. 3C).
Discussion
It was previously demonstrated that apigenin causes cell
cycle arrest via the regulation of CDK1 and p21Cip1 and the
induction of apoptosis [22]. These findings led to the
hypothesis that apigenin has potential as an anticancer
compound. In addition, several studies have shown that
apigenin-induced apoptosis involves both the intrinsic and
extrinsic apoptotic pathways [24, 25]. Thus, in the present
study, we investigated the modulation of the initiator caspase
in the extrinsic or intrinsic pathway during apigenin-induced
apoptosis.
We first examined the antiproliferative effect of apigenin
at various concentrations (1–100 µM) on MDA-MB-453
human breast cancer cells following 24 or 72 h of incuba-
tion. Apigenin significantly inhibited cellular proliferation
in a dose- and time-dependent manner. This finding is
consistent with previous data showing that apigenin may be
an effective agent against cell growth in some cancer cell
Fig. 1. Effect of apigenin on cell proliferation of human breast
cancer MDA-MB-453 cells. Cells were exposed to either
vehicle (0.1% DMSO in medium) or apigenin (1–100
µM) and incubated for 24 and 72 h. All data are reported
as the percentage change in comparison with the vehicle-
only group, which were arbitrarily assigned 100%
viability. Values are Mean ± SD (n =6 ) .  * p<0.05,
significantly different from the vehicle-only group (0.1%
DMSO in medium, that is, apigenin concentration = “0”).Apigenin Induced Caspase-dependent Apoptosis
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Fig. 2. Apigenin induced apoptosis of human breast cancer MDA-MB-453 cells. Cells were exposed to either vehicle or apigenin (at its
IC50 concentration) and incubated for 72 h. (A) MDA-MB-453 cells exposed to apigenin were observed using a Nikon inverse
phase contrast microscope. (B) To observe the apoptotic morphological changes, cells exposed to apigenin were fixed and
stained by DAPI. (C) Apoptotic population was determined by Annexin-V assay. Early apoptotic cells; right bottom, Late apop-
totic cells; right top, Live cells; left bottom. Values are Mean ± SD (n =6 ) .  * p<0.05, significantly different from the vehicle-
only group (0.1% DMSO in medium, that is, apigenin concentration = “0”).E.J. Choi et al.
J. Clin. Biochem. Nutr.
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types [26, 27].
To investigate whether this inhibition induces apoptosis,
cells exposed to apigenin at its IC50 for 72 h were stained
with DAPI. Typical morphological features of apoptosis
such as membrane blebbing were observed. Therefore, we
next investigated the apigenin-induced caspase-dependent
apoptotic signaling pathway. The expression of several
apoptosis-related genes was evaluated in MDA-MB-453
cells treated as described above. Apigenin treatment caused
the dramatic release of cytochrome c into the cytosol, which
is consistent with previous data showing that the exposure of
SK-BR-3 cells to apigenin significantly increased the release
of cytochrome c [22]. Thus, it appears that apigenin induces
apoptosis in MDA-MB-453 cells via the mitochondrial
apoptotic pathway.
We next analyzed the caspase pathway involved in the
interaction between apigenin and mitochondria. In mamma-
lian cells, apoptosis is mediated by cysteine proteases, which
are divided into initiators (e.g., caspase-8, -9, -10 and -12)
and executors (e.g., caspase-2, -3, -6 and -7). The initiators
cleave and activate the executors. The extrinsic apoptotic
pathway is initiated by the ligation of a transmembrane
death receptor with its ligand, which activates membrane-
proximal caspases (e.g., caspases-8 and -10), whereas the
intrinsic apoptotic pathway is initiated by the release of
cytochrome  c. Caspase-8 mediates signal transduction
downstream of death receptors located on the plasma
membrane [28–31]. In this study, apigenin-induced apoptosis
was associated with the extrinsic and intrinsic apoptotic
pathways as evidenced by the activation of caspases-9 and
-3, as well as caspase-8. These results are supported by the
observed activity patterns of caspases-3, -8, and -9, which
were similar to their expression patterns.
Recently, apoptosis has been identified as a useful target
in the development of anticancer therapies. Caspase-
mediated apoptosis is a major focus in the field of cancer
growth inhibition, because activation of the proteolytic
caspase cascade is a critical component in the execution of
apoptotic cell death. Our current results support the hypo-
thesis that apigenin-induced apoptosis involves the activa-
tion of both the intrinsic and extrinsic apoptotic pathways. It
is clear that apigenin may be a very useful anticancer drug
candidate for chemotherapy and, possibly, cancer preven-
tion. Because natural phytochemicals, such as apigenin,
have been reported to act on multiple molecular and cellular
targets, a better understanding of the mechanism of apigenin-
induced apoptosis is crucial.
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Fig. 3. Effect of apigenin on caspase cascade of human breast
cancer MDA-MB-453 cells. Cells were exposed to either
vehicle or apigenin at its IC50 concentration and incubat-
ed for 72 h. (A, B) Cytochrome c and various caspases
protein expressions were determined by Immunoblotting
assay. (C) Caspase-3, -8, and -9 activity was measured
using colorimetric assay. Data obtained from caspases
activity are reported as the percentage change in com-
parison with the vehicle-only group, which were
arbitrarily assigned 100% viability. Values are Mean ±
S.D. (n =6 ) .  * p<0.05, significantly different from the
vehicle-only group (0.1% DMSO in medium, that is,
apigenin concentration = “0”).Apigenin Induced Caspase-dependent Apoptosis
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